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Background: -Conotoxin AuIB interacts with 34 nAChRs and GABAB receptors, but structural determinants of these
interactions are unknown.
Results: Using alanine scanning mutagenesis and molecular dynamics, we identified residues crucial for AuIB34 nAChR
interaction.
Conclusion:We identified the key residues that mediate AuIB34 nAChR interaction.
Significance: Ability to direct -conotoxin binding to nAChRs or GABAB receptors will improve analgesic conopeptides.
-Conotoxin AuIB is a selective 34 nicotinic acetylcholine
receptor (nAChR) subtype inhibitor. Its analgesic properties are
believed to result from it activating GABAB receptors and sub-
sequently inhibiting CaV2.2 voltage-gated calcium channels.
The structural determinants thatmediate diverging AuIB activ-
ity at these targets are unknown. We performed alanine scan-
ning mutagenesis of AuIB and 34 nAChR, homology model-
ing, and molecular dynamics simulations to identify the
structural determinants of the AuIB 34 nAChR interaction.
Two alanine-substituted AuIB analogues, [P6A]AuIB and
[F9A]AuIB, did not inhibit the 34 nAChR. NMR and CD
spectroscopy studies demonstrated that [F9A]AuIB retains its
native globular structure, so its activity loss is probably due to
loss of specific toxin-receptor residue pairwise contacts. Com-
pared with AuIB, the concentration-response curve for inhibi-
tion of34 by [F9A]AuIB shifted rightwardmore than 10-fold,
and its subtype selectivity profile changed. Homologymodeling
andmolecular dynamics simulations suggest that Phe-9 ofAuIB
interacts with a two-residue binding pocket on the 4 nAChR
subunit. This hypothesis was confirmed by site-directed
mutagenesis of the4-Trp-59 and4-Lys-61 residues of loopD,
which form a putative binding pocket. AuIB analogues with
Phe-9 substitutions corroborated the finding of a binding
pocket on the 4 subunit and gave further insight into how
AuIB Phe-9 interacts with the 4 subunit. In summary, we
identified critical residues that mediate interactions between
AuIB and its cognate nAChR subtype. These findings might
help improve the design of analgesic conopeptides that selec-
tively “avoid” nAChR receptors while targeting receptors
involved with nociception.
Peptides isolated from the venom of cone snails belonging to
the genus Conus are valuable pharmacological tools, and some
are also promising drug leads (1–5). -Conotoxins are a sub-
family of these peptides and consist of 12–19 amino acid resi-
dues, including four cysteines with a characteristic CC-C-C
arrangement (type I cysteine framework) (6, 7). These four cys-
teines can yield three possible disulfide connectivities: globular
(I-III, II-IV), ribbon (I-IV, II-III), and beads (I-II, III-IV). How-
ever, naturally occurring -conotoxins typically exhibit the
“globular” conformation (7). The number of amino acids in
each of the two loops between the framework cysteine residues
is used to divide -conotoxins into subclasses. For example
those with four amino acids in loop 1 and six in loop 2 are
referred to as 4/6--conotoxins.
Nicotinic acetylcholine receptors (nAChRs)6 are transmem-
brane proteins that form cationic ligand-gated channels that
mediate fast excitatory cholinergic neurotransmission in the
central nervous system (CNS). They also have an important
regulatory role in the body, modulating the release of several
neurotransmitters. The importance of nAChRs is emphasized
by their involvement in various CNS disorders, including
Alzheimer disease, schizophrenia, pain, nicotine addiction, and
cancer (8–11).
nAChRs belong to the Cys-loop family of ligand-gated ion
channels that is characterized by a pentameric composition and
subunit arrangement in the receptor (12, 13). Seventeen
nAChR subunits have been identified (12). Six of them aremus-
cle nAChR subtypes (11 or 11) found exclusively at
neuromuscular junctions, whereas the rest (2-10,2-4) can
combine in numerous homomeric (having only  subunits) or
heteromeric (having  and  subunits) neuronal nAChR sub-
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types (8). Heteromeric receptor subtypes exhibit two distinct
subunit stoichiometries of : ratios (2:3 or 3:2) and display
different pharmacological properties (11, 14). The diversity of
neuronal heteromeric nAChR subtypes in vivo increases even
further whenmore than one / subunit is included within the
same pentamer (e.g. 324 or 362) (11).
AuIB is a 4/6--conotoxin isolated from the venom ofConus
aulicus and consists of 15 amino acid residues (15). In contrast
with most -conotoxins that inhibit 2–3 nAChR subtypes with
similar potency, AuIB only inhibits the 34 nAChR subtype
and with micromolar potency (15). Two other -conotoxins,
BuIA, an unusual 4/4--conotoxin isolated from the venom of
Conus bullatus, and the recently described 4/7--conotoxin
RegIIA from Conus regius, have been found to be considerably
more potent inhibitors of the 34 subtype, blocking it at low
nanomolar concentrations (16, 17). However, unlike AuIB, BuIA
and RegIIA are not selective for the 34 subtype but potently
block other nAChR subtypes too. Additionally, despite -cono-
toxins generally being described as competitive nAChR antago-
nists (18–20), AuIB is a non-competitive 34 antagonist (14).
-Conotoxins with a different disulfide bond connectivity
from the native form typically show losses in biological activity.
However, the ribbon disulfide isomer (I-IV, II-III) of AuIB
retains its nAChR inhibition with greater potency than that of
the native globular (I-III, II-IV) AuIB disulfide isomer in rat
parasympathetic ganglion neurons (21). Furthermore, theAuIB
ribbon isomer exhibits stoichiometry-dependent blockade of
oocyte-expressed 34 nAChRs, and unlike globular AuIB, it
competitively inhibits the 34 nAChR (14).
Interestingly, AuIB and several other-conotoxins (e.g.RgIA
and Vc1.1) exhibit analgesic properties when tested in animal
models of pain (22–24). These conotoxins inhibit various
nAChR subtypes (34, 910, and 7), but all inhibit high
voltage-activated calcium channels via G protein-coupled
GABAB receptor activationwithmuchmore potency than their
corresponding nAChR target (25–27). Therefore, GABAB
receptor-mediated suppression of N-type calcium channels
(CaV2.2) has been suggested as the common mechanism of
their analgesic action (28).
To design more effective -conotoxin analogues that could
lead to improved analgesic drugs with fewer side effects, it is
important to know the structural determinants of inhibition at
nAChRs and GABAB receptors. This would help us focus on
analgesic activity and remove the undesired side effects in engi-
neered -conotoxin analogues. Furthermore, it might help to
identify previously overlooked naturally occurring analgesic
conotoxins. Here we take the first step toward this goal by char-
acterizing the residues that are critical for -conotoxin AuIB
inhibition of 34 nAChRs. We show that the interaction
between phenylalanine (Phe) at position 9 of AuIB and 4-Tyr-
59–4-Lys-61 of the loopDon the (–) face of the4 subunit are
essential for this inhibition. A preliminary report of these
results in part has been presented in abstract form (29).
EXPERIMENTAL PROCEDURES
Peptide Synthesis—All peptides were assembled on MBHA-
Rink-Amide resin (Novabiochem) by solid-phase peptide syn-
thesis using a Liberty Microwave Peptide Synthesizer with the
in situ activation/N,N,N,N-tetramethyl-O-(1H-benzotriazol-
1-yl)uranium hexafluorophosphate protocol and Fmoc (N-(9-
fluorenyl)methoxycarbonyl) chemistry (30). Cys-3 and Cys-15
were incorporated into the peptide chain with acetamidom-
ethyl side chain protection during assembly to facilitate regi-
oselective disulfide formation. Peptides were cleaved from
the resin using trifluoroacetic acid (TFA) with tri-isopropyl-
silane and water as scavengers (9:0.5:0.5 (v/v) TFA:tri-isopro-
pylsilane:water) at 22 °C for 2 h. The TFA was then removed
under vacuum, and peptides were precipitated with ether, fil-
tered, dissolved in 50% acetonitrile containing 0.05% TFA, and
lyophilized. Crude peptides were purified by reversed-phase
high performance liquid chromatography (RP-HPLC) on a C18
column using a gradient of 0–80% B (A, H2O, 0.05% TFA; B,
90% CH3CN, 10% H2O, 0.045% TFA) in 80 min. Analytical RP-
HPLC and electrospray mass spectrometry confirmed the
purity and molecular mass of synthesized peptides.
The first disulfide bond in each peptide was formed by incu-
bating peptides in 0.1 M NH4HCO3 (pH 8.2, 0.3 mg/ml) over-
night at 22 °C, then purifying them by RP-HPLC. The second
disulfide bond was formed by incubating peptides with iodine
in acidic conditions. Peptides were dissolved in 50% aqueous
acetic acid (0.5mg/ml). To this solution 100l of 1MHCl/mgof
peptide was added, then a solution of 0.1 M I2 in 50% acetic acid
was slowly added until the solution became pale yellow. The
reaction mixture was stirred for 12 h at 22 °C in the dark.
The reaction was quenched by adding 1 M ascorbic acid until
the mixture became colorless. The peptide was purified by RP-
HPLC, and fractions were combined after analytical RP-HPLC
confirmed purity. Electrospray mass spectrometry was used to
confirm the peptide identity.
NuclearMagnetic Resonance (NMR) and Circular Dichroism
(CD)—NMR spectra for all AuIB analogues were recorded on
samples dissolved in 90% H2O and 10% D2O at a pH of 4.
Bruker Avance 500 and 600 MHz NMR spectrometers were
used to acquire spectra, including 1H, total correlation spec-
troscopy (TOCSY) and nuclearOverhauser effect spectroscopy
(NOESY) data, as described previously (18, 31), and processed
usingTopspin (Bruker). All spectrawere recorded at 290K, and
chemical shifts were referenced to the residual water signal at
4.85 ppm. Processed spectra were analyzed and assignedwithin
the program Sparky (32).
For CD spectroscopy experiments, 70 M concentrations of
each peptide were dissolved in 20mM sodium phosphate buffer
at pH 7. To examine the helical propensity of each isomer, CD
data were also obtained for each product after 30% tetrafluo-
roethene was added to the solution. Spectra were acquired on a
Jasco J-810 spectropolarimeter, which was routinely calibrated
using 0.6% (w/v) ammonium-D-camphor-10-sulfonate. All
experiments were conducted at room temperature (21–23 °C)
under a nitrogen atmosphere (15 ml/min). The experimental
parameters were set to a scanning speed of 50 nm/min,
response time of 1 s, sensitivity range of 100 millidegrees, and a
step resolution of 1 nm. Absorbance was measured in the far
UV region (185–260 nm) using a 1-mm path length quartz
cuvette. Each recording was an accumulation of four scans. To
eliminate any possible interference from the solvent, cuvette,
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and spectropolarimeter optics, we subtracted CD spectra of the
pure solvents from each sample.
Protein Sequence Alignment—The National Institute of
Health’s online Constraint-based Multiple Alignment Tool,
COBALT (www.ncbi.nlm.nih.gov), was used to align protein
sequence, and conservative domains were taken into account.
Residues of nAChR subunits were numbered according to the
sequences of the mature proteins that lacked the signal peptide
at the start of their sequences.
Site-directed Mutagenesis of 3 and 4 nAChR Subunits—
Constructs in which Trp-59, Lys-61, or both 4 nAChR resi-
dues were substituted by alanine ([W59A]4, [K61A]4, and
[W59A][K61A]4, respectively) were generated using the
Geneart Site-directed Mutagenesis System (Invitrogen catalog
no. A13282) and the following primers: 5-cat gac cac cag cat
cgc gct gaa aca gga atg gac tga cta cc-3 and 5-ggt agt cag tcc att
cct gtt tca gcg cga tgc tgg tgg tca tg-3 for [W59A]4; 5-cat gac
cac cag cat ctg gct ggc aca gga atg gac tga cta cc-3 and 5-ggt agt
cag tcc att cct gtg cca gcc aga tgc tgg tgg tca tg-3 for [K61A]4;
5-cat gac cac cag cat cgc gct ggc aca gga atg gac tga cta cc-3 and
5-ggt agt cag tcc att cct gtg cca gcg cga tgc tgg tgg tca tg-3 for
[W59A][K61A]4. Gln-198 of the3 subunit was substituted
to alanine ([Q198A]3) in the same way using primers 5-ctg
tga gga gat cta cgc aga cat cac gta ctc gc-3 and 5-gcg agt acg tga
tgt ctg cgt aga tct cct cac ag-3. All point mutations were con-
firmed by sequencing.
cRNA Preparation—Plasmid DNAs encoding rat 3, 4, 9,
10, 2, and 4 nAChR subunits and human 7 nAChR sub-
units were obtained fromDr. J. Patrick, Baylor College of Med-
icine,HoustonTX,Dr. J. LindstromUniversity of Pennsylvania,
Philadelphia PA, and OriGene Technologies Inc., Rockville
MD. The plasmids were linearized with appropriate restriction
enzymes, and cRNA was synthesized in vitro using a SP6 or T7
in vitro transcription kit (mMessage mMachine; Ambion, Fos-
ter City, CA). RNA for different nAChR subunits to be co-in-
jected into the same oocytes was synthesized in parallel on the
same day using identical procedures to maximize the consis-
tency of concentration and purity between subunits.
Oocyte Preparation andMicroinjection—Stage V-VI oocytes
were obtained from Xenopus laevis, defolliculated with colla-
genase (Type I, Sigma) at 3 mg/ml, and incubated at 18 °C in
sterile ND96 solution (96mMNaCl, 2 mMKCl, 1.8 mMCaCl2, 1
mM MgCl2, and 5 mM HEPES at pH 7.5) supplemented with 50
g/liter gentamycin (Sigma). Glass pipettes for microinjection
were pulled from glass capillaries (3–000-203 GX, Drummond
Scientific Co.). The cRNAs were diluted in water to the appro-
priate concentrations (0.1 ng/nl), and 5 ng of RNA was
injected into each oocyte using a microinjector (Nanojet,
Drummond Scientific Co.). Electrophysiological recordings
were carried out 2–7 days after microinjection.
Electrophysiological Recordings and Data Analysis—Two-
electrode voltage clamp recordings from oocytes were carried
out at room temperature using a GeneClamp 500B amplifier
(Molecular Devices Corp., Sunnyvale, CA) at a holding poten-
tial of 80 mV. The voltage-recording and current-injecting
electrodes were pulled from borosilicate glass (GC150T-15,
Harvard Apparatus Ltd.) and had resistances of 0.3–1.5megao-
hms when filled with 3 M KCl. Oocytes were continuously per-
fused in a recording chamber with a volume of 50 l, with
ND96 solution at 2 ml/min, applied by a gravity-fed perfusion
system. nAChR-mediated currents were evoked by pipetting
100 l of acetylcholine (ACh) into the bath when the perfusion
was temporarily halted. ACh concentration was 50 M unless
specified otherwise. Oocytes were preincubated with the pep-
tide for 5 min, then ACh and the peptide were co-applied.
Peak ACh-evoked current amplitude was recorded before and
after peptide incubation using pClamp 9 software (Molecular
Devices). The effects of native AuIB and its peptide analogues
on ACh-evoked nAChR-mediated currents were defined as
peak current amplitudes relative to the average peak current
amplitude of 3–5 control ACh applications, recorded before
preincubation with the peptides. Concentration-response
curves for AuIB and [F9A]AuIBwere fitted by unweighted non-
linear regression to the logistic equation,
Ex  EmaxX
nH/XnH IC50
nH (Eq. 1)
where Ex is the response,X is the peptide concentration, Emax is
the maximal response, nH is the slope factor (Hill slope), and
IC50 is the peptide concentration that gives 50% inhibition of
the maximal response. All electrophysiological data were
pooled (n  3–6 for each data point) and represent the arith-
metic means S.E. of the mean. One-way analysis of variance
followed by Bonferroni’s post hoc test was used to compare
current amplitudes affected by AuIB analogues with those of the
native peptide. Data were statistically analyzed using SigmaPlot
Version 11.0 (Systat Software Inc., San Jose, CA) or Prism5
(GraphPad Software Inc., La Jolla, CA).
Molecular Modeling and Docking Simulation—Homology
models of the extracellular ligand binding domain of the rat
(3)2(4)3nAChRbound toAuIB, [F9A]AuIB,or [F9Y]AuIBwere
constructedusing the crystallographic coordinates ofAplysia cali-
fornica acetylcholine-binding protein (AChBP) co-crystallized
with the double mutant -conotoxin PnIA[A10L,D14K] (Protein
Data Bank accession code 2BR8) as a template. This template
was chosen to provide a suitable 4/7 -conotoxin-bound con-
formation of the receptor for subsequent molecular dynamics
(MD) simulations and analyses.
AuIB and mutant peptides were modeled bound to the two
3()4() receptor binding sites using the geometry of the
PnIA mutant in the AChBP crystal structure as a template. Rat
3 and 4 sequences were obtained from the Swiss-Prot data-
base (codes P04757 and P12392, respectively) and aligned with
the template sequence using the ClustalW server. BLOSUM
was used as the scoring matrix. With the multiple alignment as
input, 10 AuIB34, [F9A]AuIB34, and [F9Y]AuIB34
complex models were generated using Modeler9v6. The top-
rankingmodels were selected and validated using PROCHECK.
MD simulations were carried out on the top models of both
receptor complexes.
MD Simulations—Before MD simulations, the energies of
the complexes wereminimized using the steepest descent algo-
rithm and an energy gradient convergence criterion of 0.01 kcal/
mol/Å. Each receptor complex was placed in icosahedral simula-
tion boxes with edge lengths of 100	 100	 100 Å and solvated
with34,000TIP3Pwatermolecules.Toneutralize charge andpro-
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vide a salt concentration of 150 mM, 94 Na and 70 Cl ions
were added to the solvent. All simulations were performed using
GROMACS Version 4.5 (75) with the CHARMM27 forcefield
(with cmap) (76, 77). All subsequent simulations were per-
formed using a constant particle number, pressure, and tem-
perature ensemble. Temperature was maintained at 300 K
using the Nose-Hoover temperature coupling algorithm, and
pressure was maintained at 1 atm using Berendsen’s pressure
coupling algorithm. Time steps of 2 fs were used to integrate all
simulations. Solvent equilibration simulations of 100 ps lengths
were performed. The non-hydrogen atoms of the receptor and
peptides were positionally restrained so the solvent and ions
could relax from an initially semi-crystalline structure. “Data
collection” simulations of both complexes were then con-
ducted, and all atoms of the system were free to undergo
dynamics. Each complex was simulated for 100 ns. All analyses
were performed on the final 20 ns of the trajectories to reduce
bias from initial homology model conformations. Molecular
graphics were produced using VMD Version 1.9.2 (78). All
analyses were done using a combination of VMD, GROMACS
analysis software suite, and in-house scripts.
RESULTS
Alanine Scanning Mutagenesis Identifies Residues in the
AuIB Sequence That Are Critical for Its Interaction with the
34 nAChR Subtype—To find residues in the AuIB sequence
that contribute most to 34 nAChR inhibition, we performed
alanine scanningmutagenesis of the peptide.We systematically
substituted each of the original residues to alanine, except for
the four cysteines essential formaintaining the peptide globular
structure and the native alanine at position 10 (see Fig. 1,A and
B). All peptides were successfully synthesized using solid-phase
peptide synthesis and a regioselective approach to form disul-
fide bonds to produce the globular disulfide framework. For
future reference, we refer to globular AuIB as native AuIB. Each
alanine mutant structure was analyzed using NMR and CD
spectroscopy. The NMR spectral data for each peptide except
[P6A]AuIB were successfully assigned whereby Hi–NHi1
NOE connectivities observed in NOESY spectra were used in
the sequential assignment of the individual spin systems deter-
mined from TOCSY spectra.
The [P6A]AuIB mutant exhibited broadened signals and
multiple conformations in the TOCSY and NOESY spectra, so
could not be assigned. The loss of secondary structure in the
[P6A]AuIB mutant was confirmed by CD spectroscopy (Fig.
1C). Pro-6 is the only highly conserved amino acid residue in
-conotoxins apart from the cysteines and is responsible for
helix initiation by inducing the 310 helix turn in the peptide
backbone (33, 34). Mutation of Pro-6 to alanine has also been
shown to disrupt the -conotoxin Vc1.1 structure (35).
Secondary H chemical shifts represent the difference
between an observed H chemical shift and that of the corre-
sponding residue in a random coil peptide. They are strong
indicators of thepresenceof a secondary structure (36). Secondary
shift analysis of the chemical shift data indicated that, for native
AuIB and analogues [G1A]AuIB, [S4A]AuIB, [P7A]AuIB,
[F9A]AuIB, [T11A]AuIB, [P13A]AuIB and [D14A]AuIB, residues
6–10 have negative H secondary shifts (Fig. 1D). These nega-
tive H secondary shifts indicate a helical region, which is con-
sistent with the previously reported three-dimensional struc-
ture of native AuIB (21) and other -conotoxin structures
reported to date (37). Interestingly, NMR secondary shift data
for [Y5A]AuIB and [N12A]AuIBweremore consistent with the
ribbon isomer of AuIB (21) despite using a regioselective disul-
fide bond formation strategy to form the native (globular) iso-
mer (Fig. 1D). This was confirmed by CD spectroscopy (Fig.
1C).
The effect of point modifications in the AuIB analogues on
34 nAChR-mediated current inhibition was examined by
two-electrode voltage clamp recordings in oocytes expressing
the 34 nAChR subtype. The relative amount of inhibition
AuIB alanine-substituted analogues produced was compared
with that of non-modified peptides at a fixed concentration (3
M; IC50 AuIB (14)) (Fig. 2, A and B).
Only three residues in the AuIB sequence significantly
reduced inhibition of relative peak ACh-evoked current ampli-
tude when alanine was substituted for them. These were Gly-1
(0.82  0.11, n  3; p 
 0.05), Pro-6 (1.02  0.07, n  3; p 

0.001), and Phe-9 (1.07 0.15, n 3; p
 0.001) comparedwith
a relative peak current amplitude of 0.51  0.07 (n  6)
obtained in the presence of native AuIB (Fig. 2B). Interestingly,
Gly1 replacement by Ala reduced 34 nAChR inhibition,
although Gly1 does not belong to either loop 1 or loop 2 of
AuIB, which are thought to be the primary mediators of
-conotoxin interaction with nAChRs (6, 7). Unlike the
[G1A]AuIBmutation, which retainedminor inhibitory activity,
P6A and F9A analogues exhibited a complete loss of inhibitory
activity. As theNMRandCDdata showed that secondary struc-
ture of [P6A]AuIB is irregular (Fig. 1, C and D), we concluded
that this peptide’s loss of inhibitory activity was due to disrup-
tion in the three-dimensional structure. This is not surprising,
as Pro-6 is believed to be responsible for inducing the 310 helix
turn in the backbone of -conotoxins (33, 34). In contrast,
[F9A]AuIB NMR and CD spectrum data were consistent with
the native AuIB structure (Fig. 1, C and D). This led us to con-
clude that the F9A substitution is specific and relevant to the
peptide-receptor interaction rather than a general disruption of
the peptide structure.
Characterization of [F9A]AuIB Inhibition of the34 nAChR
Subtype—Our next step was to probe the degree to which
[F9A]AuIB inhibitory activity is impaired by modifying the Ala
to Phe substitution. Because the [F9A]AuIB analog was not
active at IC50 concentration of the native AuIB (3 M) (Fig.
2A), we tested this analog at higher concentrations, up to
the highest practical concentration available (30 M). The
[F9A]AuIB analog applied at 10 M mildly inhibited ACh-
evoked currents, with the amplitude reduced to 0.77  0.04
(n  4) of normalized control currents (Fig. 3, A and B). This
indicates that Phe to Ala substitution at position 9 of AuIBmay
strongly reduce the affinity of the modified peptide for 34
nAChRs but does not disrupt peptide-receptor interaction alto-
gether. However, native AuIB completely blocked the current
at this concentration (0.05  0.01, n  6) (Fig. 3, A and B). A
concentration of 30 M [F9A]AuIB inhibited 55% of current
amplitude (0.45  0.07, n  3). The resulting concentration-
response curve demonstrates a rightward shift, indicating
-Conotoxin AuIB Interaction with34 nAChRs
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[F9A]AuIB interactionwith34 nAChRs ismarkedly reduced
(Fig. 3B).
The Selectivity Profile of [F9A]AuIB for nAChR Subtypes—
Previously, most -conotoxins that act on neuronal nAChRs
were shown to have only relative selectivity in the sense that
they inhibit two to three nAChR subtypes with similar potency
and rarely inhibit just one nAChR subtype (6, 7). To date, AuIB
is the only -conotoxin shown to selectively inhibit the 34
nAChR subtype (15). As described above, substituting Phe-9 to
Ala in AuIB led to complete loss in activity at 34. We also
assessed the pharmacological profile of [F9A]AuIB at other
nAChR subtypes. When tested, [F9A]AuIB (3 M) exhibited
only 16.2% inhibition of relative current amplitude (0.84 0.1,
n  3) at 32 nAChRs, whereas no activity was observed at
44 nAChRs (n 5) (Fig. 4A). However, we found that 3 M
[F9A]AuIB produced minor potentiation at the homomeric 7
nAChR subtype (1.27  0.04, n  3). Surprisingly, moderate
inhibition of the 910 nAChR subtype was observed (0.59 
01%, n 3) (Fig. 4A). We next tested higher concentrations of
[F9A]AuIB at 7 and 44 nAChR subtypes. Unlike the 34
FIGURE 1.Characteristics of AuIB and its analogues.A, sequence of amino acid residues in-conopeptide AuIB. The disulfide bonding pattern characteristic
to the native AuIB globular isoform is indicated above the sequence: 2CCX4C
8 (I–III) and 3CX4CX6C
15 (II–IV). The residues between cysteines 3CX4C
8 and 8CX6C
15
form the peptide loop 1 and loop 2, respectively. B, three-dimensional visualization of the AuIB structure (Protein Data Bank accession code 1MXN). Note that
the second longer loop folds in an -helical structure. C, CD spectra of Ala analogues compared with those of native globular AuIB revealed that [G1A]AuIB
(open squares), [S4A]AuIB (orange triangles), [P7A]AuIB (purple circles), [F9A]AuIB (red squares), [T11A]AuIB (open triangles), [P13A]AuIB (open diamonds), and
[D14A]AuIB (asterisks) analogues have similar spectra to globular AuIB (black circles). [Y5A]AuIB (inverted green triangles), [P6A]AuIB (blue diamonds), and
[N12A]AuIB (inverted open triangles) analogues lack the -helix characteristic CD absorption and show a single peak in the spectrum only, indicating their
secondary structure is disrupted. D, NMR secondary shift analysis of the -conotoxin AuIB Ala analogues. The shift values of [G1A]AuIB, [S4A]AuIB, [P7A]AuIB,
[F9A]AuIB, [T11A]AuIB, [P13A]AuIB, and [D14A]AuIB comparedwith native globular AuIB (black circles) highlight the similarity in values across the full length of
the peptide and confirm the secondary structure of these mutated peptides is well preserved. A series of negative values observed from residues 6–10
indicates there is a helical secondary structure in this region of the peptides, which is consistent with the three-dimensional structure of native globular AuIB.
The [Y5A]AuIB and [N12A]AuIB analogues had H secondary shift values consistent with the ribbon isomer of AuIB (blue hexagons).
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nAChR subtype, where higher concentrations of [F9A]AuIB
significantly inhibited ACh-evoked currents (Fig. 4B, see also
Fig. 3B), no significant change in relative current amplitudewas
observed at 44 nAChRs by 10 M (0.88 0.07, n 4) or 30
M (0.85 0.1, n 4) of [F9A]AuIB. Similarly, at 7 nAChRs
neither 10 M (1.01 0.15, n 4) nor 30 M (0.83 0.35, n
6) [F9A]AuIB produced any potentiation or inhibition of ACh-
evoked current amplitude (Fig. 4B).
Homology Modeling and MD Simulations Suggest Loss of
Interactions between AuIB and Key Receptor Residues When
Ala Is Substituted for Phe-9—Having established that position 9
Phe in AuIB is crucial for the peptide inhibiting 34, we used
atomistic simulations of native AuIB and the [F9A]AuIB
mutant bound to34 to providemolecular-level explanations
of why the mutation so markedly reduces inhibition. In partic-
ular, whereas experimental alanine scanning mutagenesis on
AuIB identified peptide residues crucial for its efficacy, homol-
ogy modeling andMD simulations identified receptor residues
that might play important roles in AuIB inhibition of 34
nAChR. Representative homology models of AuIB-bound
34 are shown in Fig. 5, A and B.
To elucidate which receptor residues probably need contact
with the peptide for inhibition to occur, we first calculated the
average number of interatomic contacts between native AuIB
or [F9A]AuIB and each receptor ectodomain residue. We then
subtracted the number of contacts between each receptor res-
idue and [F9A]AuIB from the number of contacts between each
receptor residue and native AuIB. This measured the loss (or
gain) of peptide contacts at each receptor residue caused by the
mutation at AuIB position 9. Receptor residues with a negative
contact difference might be important for AuIB inhibition. Fig.
FIGURE2.Alanine-scanningmutagenesisofAuIB.A, representative current
traces showing inhibition of 34 ACh-evoked currents by native and ala-
nine-substituted AuIB analogues (3 M). B, bar graph showing ACh-evoked
current inhibition of 34 nAChR by alanine-substituted AuIB analogues
(filled bars) compared with native AuIB (open bar). All peptides used in this
experiment were tested at 3 M. Data represent the means S.E., n 3–6. *
indicates p 
 0.05; *** indicates p 
 0.001 for relative reduction of current
inhibition versus native AuIB.
FIGURE3.The [F9A]AuIBanalogexhibits substantially reducedactivityat
34 nAChR. A, representative ACh-evoked current traces mediated by
34 nAChRs in the absence and presence of native AuIB and [F9A]AuIB (10
M). Note the substantially reduced inhibition by the [F9A]AuIB. B, concentra-
tion-response curves for inhibition of ACh-evoked currents by native AuIB
(open circles) and analog [F9A]AuIB (filled squares). Data represent the
means S.E., n 3–6. Note that [F9A]AuIB does not attenuate inhibition but
shifts the curve rightward.
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5C shows the 34 receptor residues and mutation-induced
changes in terms of the number of contacts with the peptide.
At the 3() face, loss of peptide contact at several residues
(e.g. Tyr-93, Cys-192, and Cys-193) is offset by increased con-
tact at others (e.g. Ile-188, Tyr-190, Glu-195, Tyr-197, Gln-198,
andAsp-199). Therefore, on average, peptide contact at the ()
face slightly increased. In contrast, at the 4() face, the F9A
mutation caused widespread loss of contact across many resi-
dues (with notable exceptions at Arg-115). Therefore, remov-
ing the bulky phenyl side chain at position 9makesAuIB detach
from the 4() face. This slightly increased the peptide’s num-
ber of interatomic contacts at the opposing 3() face.
Based on this analysis, we propose several specific receptor
residues that are especially important for AuIB inhibition of
34. First, because we demonstrated that the F9A mutation
substantially reducesAuIB inhibitory efficacy, we examined the
receptor residues that bind Phe-9, because these are probably
crucial for AuIB inhibition of 34. The homology model and
MD simulation trajectory of wild-type AuIB/34 suggested
that Phe-9 makes contact exclusively at the 4() face, with its
phenyl ring sandwiched between the Trp-59 indole ring and
hydrocarbon segment of the Lys-61 side chain (Fig. 6B). As
expected, both of these residues lose contact with the peptide
when position 9 of AuIB is substituted (Fig. 5C).
The geometry of contacts between AuIB-Phe-9 with
4-Trp-59 and4-Lys-61 suggests that cation-	 and	-	 inter-
actionsmay be important inAuIB inhibition of34.However,
we caution that the CHARMM27 force field does not explicitly
account for interactions involving	 electrons and acknowledge
that methods which explicitly model cation-	 interactions are
needed to produce quantitatively accurate geometries involv-
ing charged and aromatic side chains. Nonetheless, the force
field we used partially mimicked cation-	 interactions and pre-
dicted Lys-Phe and Phe-Trp interaction geometries that are
qualitatively in agreement with similar interactions observed in
thePDB. In particular, our simulation suggests that contacts are
made between 4-Lys-61 and the AuIB-Phe-9 phenyl ring pri-
marily through themethylene carbons adjacent to the amine. In
the PDB, Lys is known to engage with 	 systems more com-
monly via carbon (38, 39). Furthermore, our simulation sug-
gests an offset-stacked interaction between 4-Trp-59 and
AuIB-Phe-9. This geometry was identified as a common struc-
tural motif in Trp-Phe interactions in the PDB (40).
In addition, at the3() face, there ismodest but statistically
significant loss of contact between AuIB and both C-loop cys-
teines when position 9 of AuIB is substituted (Fig. 5C). This is
due to reduced contact between theAuIB-Cys2/8 cysteines and
3-Cys-192/193. A snapshot from the MD trajectory of the
native AuIB (Fig. 6C) illustrates close contact between the Cys-
2–8 sulfurs of the peptide and the Cys-192/193 sulfurs of3. In
contrast, a similar snapshot for the [F9A]AuIB trajectory (Fig.
6D) illustrates loss of close contacts between the peptide and
receptor disulfides. This result is especially intriguing, given
that direct contact between peptide and C-loop cysteines is
proposed to be essential for the peptide competitive antago-
nism of nAChRs, based on results fromdicarba-conotoxin vari-
ants (41). Fewer close interatomic contacts between AuIB and
3 C-loop cysteines, indirectly caused by substituting Ala for
Phe at position 9 (which lies on the opposite side of the peptide),
may contribute to loss of inhibitory efficacy of this mutant.
Therefore, we propose that Phe-9 has two roles in the AuIB
inhibition of34: 1) direct contactwith4-Trp-59 andLys-61
and 2) indirect facilitation of close contact between AuIB Cys-
2/8 and 3-Cys-192/193.
Site-directed Mutagenesis of the 4 nAChR Subunit Verifies
the Putative Binding Pocket on the 4 as the Site of Interaction
between AuIB Phe-9 and 34 nAChRs—Homology modeling
andMD simulations indicated that the two residues on the ()
(complementary) side of the 4 subunit sandwich Phe-9 of
AuIB.We further focused on the contribution of these residues
to AuIB activity at the 34 nAChR. We used site-directed
mutagenesis of the 4 nAChR subunit to verify what role
4-Trp-59 and 4-Lys-61 have in forming a binding pocket for
AuIB Phe-9. When 4-Trp-59 and 4-Lys-61 were both
mutated to alanines ([W59A][K61A]4), the mutant 34
receptor produced much smaller ACh-evoked peak current
amplitudes than those of wild-type nAChR. The same effect
FIGURE 4. nAChR subtype selectivity profile of [F9A]AuIB. A, bar graph
showing relative ACh-evoked current amplitude in the presence of 3 M
[F9A]AuIB tested at different nAChR subtypes. B, comparison of effects of
three different [F9A]AuIB concentrations (3, 10, and 30 M) on ACh-evoked
current amplitude at r34, h7, and r44 nAChR subtypes. Data represent
the means S.E., n 3–6. * indicates p
 0.05 for relative change of current
inhibition at various nAChR subtypes versus 34 nAChRs (A) and for relative
change of current inhibition at 10 and 30 M compared with 3 M peptide
concentration (B).
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FIGURE 5.MD simulation suggests that substituting Ala for Phe at position 9 of AuIB reduces interaction between AuIB and the4 nAChR subunit. A
model shows 34 nAChR in the (3)2(4)3 stoichiometry in top view (A) and its 3()/4() interface in side view (B). AuIB binding to the receptor is shown
in red. C, contact difference bar graph representing quantification of results from homology modeling and MD calculations (20 ns). Shown is the number of
interatomic contacts in the 3()/4() subunit interface (
0.45 nm) between each receptor residue and the bound peptide lost (negative y axis values) or
gained (positive y axis values) as a result of substituting Ala-9 for Phe-9. Note that the effect at the4() side is a loss of interaction between [F9A]AuIB and the
4 subunit. D, a contact difference bar graph for [F9Y]AuIB indicates mutation to Tyr results in substantial loss of contacts between the peptide and several
aromatic cage residues at the 3 (Tyr-93, Trp-149, Tyr-197) and 4 (Trp-59) subunits. Furthermore, the number of contacts with the 3-Cys192/193 sulfurs is
reduced.
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was present when 4-Trp-59 was mutated alone ([W59A]4).
Therefore, we used a high agonist concentration (2.5 mM ACh)
to evoke currents in all groups to create a meaningful compar-
ison. The high agonist concentration should not interfere with
AuIB inhibition, because AuIB inhibits the 34 nAChR non-
competitively irrespective of ACh concentration (14). We
assessed the effect of 4 mutations using a high concentration
of native AuIB (10 M), which efficiently inhibits wild-type
34 nAChRs (14).
The [W59A][K61A]4 mutation almost completely abol-
ished inhibition by native AuIB (0.89 0.08, n 6) compared
with wild-type 4 (0.15  0.07, n  5) (Fig. 7, A and B). The
same abolishing effect was observed with the [W59A]4
mutant in which only 4-Trp-59 was changed to Ala (0.89 
0.05, n  3). However, slightly more inhibitory activity
remainedwith the [K61A]4mutation (0.66 0.03, n 3) (Fig.
7, A and B). This suggests that 4-Trp-59 and 4-Lys-61 help
form the pocket for interaction between the receptor and Phe-9
of AuIB. However, in contrast with the auxiliary role of 4-Lys-
61, interaction between the two aromatic residues of the pep-
tide and receptor (Phe-9-AuIB4-Trp-59) appears indispensa-
ble for mediating AuIB inhibitory effect. We also tried to make
a control mutation of a tryptophan further down the sequence
from the ACh binding site ([W64A]4), but no ACh-induced
current was elicited at the mutated receptor.
Our model suggested that Tyr-5 of AuIB probably interacts
with the backbone of Gln-198 of the 3 subunit (Fig. 6A). A
mutation of 3-Gln-198 to alanine ([Q198A]3) had only a
minor, but significant, effect on currents evoked by ACh (50
M) and inhibited by AuIB (10 M) (0.25  0.02, n  5, p 
0.032 for [Q198A] mutant; 0.17 0.02, n 4 for native AuIB).
However, mutation of its putative partner, Tyr-5 of AuIB
([Y5A]AuIB), did not reduce wild-type 34 nAChR inhibition
at 3M (0.33 0.02,n 5) (see Fig. 2B). Therefore,3-Gln-198
interaction with AuIB-Tyr-5 is unlikely to determine AuIB
activity.
How Side Chain Size and Hydrophobicity at Position 9 of
AuIB Affect Inhibition at the 34 nAChR—Given the critical
interaction between AuIB-Phe-9 and 4-Trp-59 and the pro-
posed importance of cation-	 and 	-	 interactions for the
inhibitory activity of AuIB, we assessed how side chain size,
aromaticity, and hydrophobicity of the amino acid residue at
position 9 in the AuIB sequence affect nAChR inhibition. In
particular, we sought to find position 9 substituents that may
better fit the Trp-59–Lys-61 pocket on the 4 nAChR subunit
than Phe. We probed the inhibitory action of AuIB analogues
substituted at position 9 by large aromatic (Tyr, Trp, 3-(2-
naphthyl)-L-alanine (NAL)) and small (Gly) side chains onwild-
type 34 nAChRs. CD analysis confirmed that the globular
peptide structure was retained in all of these analogues
([F9G]AuIB, [F9Y]AuIB, [F9W]AuIB, [F9NAL]AuIB) (Fig. 8A).
Substituting Phe-9 to glycine ([F9G]AuIB, 10 M) dramatically
reduced inhibition (0.90  0.04, n  3; p 
 0.001) compared
with native AuIB (0.047 0.01, n 6) (Fig. 8B). This is consis-
tent with our proposed model in which AuIB interaction with
the binding pocket on the4 subunit is crucial. This interaction
is presumably absent when Phe-9 is replaced by the side chain-
free Gly.
Phe-9 mutation to the slightly larger and less hydrophobic
Tyr ([F9Y]) significantly reduced 34 nAChR inhibition
(0.42 0.07, n 3; p
 0.001) (Fig. 8B) compared with native
AuIB. Homology modeling and MD simulation of the
[F9Y]AuIB34 interaction suggest that mutation to Tyr
results in substantial loss of contacts between the peptide and
several aromatic cage residues at the 3 (Tyr-93, Trp-149, Tyr-
197) and 4 (Trp-59) subunits, as shown by contact difference
plot (Fig. 5D) The latter residue is of special interest given its
known importance for AuIB inhibition (discussed above).
Inspection of the structural model indicates that the aromatic
ring of Tyr-9 in [F9Y]AuIB directly contacts the hydrocarbon
segment of4-Lys-61. But unlike the Phe-9 of native AuIB (Fig.
6B), the Tyr-9 side chain does not contact Trp-59 4. Further-
more, mutation to Tyr results in loss of contact with the
3-Cys-192/193 sulfurs (Fig. 5D). Together with the electro-
physiology data, our model of [F9Y]AuIB34 interaction fur-
ther supports our hypothesis that position 9 contact with the
4-Tyr-59 and 3 disulfide structural motif is essential for
AuIB activity against 34.
Another AuIB analog in which Trpwas substituted for Phe-9
(F9W) substantially reduced inhibition (0.80 0.07, n 3; p

FIGURE6.HomologymodelingandMDsimulationofAuIB 34binding.
A, main interacting residues between AuIB and 3 subunit. Receptor back-
bone is in transparent blue ribbon form, with receptor residues of interest in
Corey-Pauling-Koltun representation and indicated with arrows. Peptide
backbone is in opaque red ribbon form,with residues of interest shown as van
der Waals spheres and indicated with arrows. B, main interacting residues
between AuIB and 4 subunit. Receptor backbone is in transparent yellow
ribbon form. At the 3() 4() interface, the only “unique 3” residuemak-
ing direct contact with AuIB is Gln-198. However, this occurs via backbone
only. On the4 subunit, Phe-9 of AuIB is stabilizedby Lys-61 andTrp-59of the
receptor. Phe-9 substitution to alanine results in loss of interactions with
both these residues. Trp-59 is common to all neuronal nAChRs and so does
not determine AuIB selectivity. Lys-61 is unique to the 4 subunit, so
determines AuIB selectivity for34. C, snapshot illustrating close contact
between AuIB-Cys2 (van der Waals spheres) and 3()-Cys-192 and -Cys-
193 (Corey-Pauling-Koltun representation).D, snapshot illustrating loss of
close contact between [F9A]AuIB-Cys2 and 3()-Cys192 and -193, which
might be partly responsible for loss of inhibitory activity of [F9A]AuIB and
[F9Y]AuIB.
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0.001) presumably due to steric clashes. Indeed, automated
blind docking of [F9W]AuIB to 34 using Autodock (42) with
all peptide side chain torsions free to rotate showed that none of
the docking solutions involved binding of analog [F9W]AuIB to
the canonical C-loop pocket. In contrast, docking of both native
and [F9Y]AuIB predicted binding conformations very close to
that of the double mutant PnIA-AChBP co-crystal structure
(2BR8) (data not shown). An analog with an even larger unnat-
ural amino acid, NAL, to substitute Phe-9 ([F9NAL]AuIB) also
showeddramatically reduced inhibition (0.82 0.07,n 3;p

0.001) (Fig. 8B). The NAL was attached to the 2-position of the
Ala residue. Unlike the Trp residue, which has an N-heterocy-
clic five ring, NAL has a homocarbocyclic six ring.
Together, these results demonstrate that side chain size,
aromaticity, and hydrophobicity at position 9 of AuIB are
important for interaction between the peptide and 4 sub-
unit of the 34 pentamer. In contrast with the above men-
tioned analogues with substitutions at position 9, inhibition
in a control AuIB analog with a histidine substitution at posi-
tion 12 (N12H) was not significantly impaired (0.069 
0.003, n  3) (Fig. 8B).
DISCUSSION
Using alanine scanning mutagenesis, we identified three res-
idues in theAuIB sequence (Gly-1, Pro-6, and Phe-9) that affect
inhibition of 34 nAChRs. The Gly to Ala substitution only
moderately reduced inhibition. Homology modeling of the
AuIB34 complex suggests that theN terminusNH3 ofAuIB
forms a salt bridge with the 4-Asp-172 side chain. The G1A
mutation introduces a non-polar CH3 side chain that may
weaken the favorable interaction between the peptide N ter-
FIGURE 7. The effects of pointmutations in the4 nAChR subunit onAuIB inhibition. A, representative ACh-evoked currents showing native AuIB (10M)
inhibition of 34 nAChRs compared with the 4 subunit double mutant (W59A K61A) and two single point mutants of 4, W59A and K61A. B, bar graph
showing quantification of AuIB (10M) inhibition at the 4 nAChR subunit mutants and wild-type 34 nAChR. AuIB inhibition is abolished in [W59A]4 and
the [W59A][K61A]4 double mutant, confirming these residues have a key role in AuIB binding. Note the intermediate effect of K61Amutation, suggesting
it has an auxiliary role in forming the binding pocket for the hydrophobic interaction with Trp-59, which is key for inhibition. Note that only high ACh
concentration elicited measurable currents in the W59AK61A mutant. Therefore, 2.5 mM ACh was used as an agonist to compare inhibition in the mutants
and wild-type receptors. Data represent the means S.E., n 3–6. ** indicates p
 0.005; *** indicates p
 0.001 for relative reduction of current inhibition
versuswild-type 34 nAChRs.
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minus and 4-Asp-172 side chain. Additionally, in a recent
study investigating N-terminal post-translational modifica-
tion of -conotoxin MI, truncation of the N-terminal resi-
due decreased the affinity for the muscle-type nAChR, a direct
pharmacological effect indicating the N-terminal residues are
important for bioactivity (43). -Conotoxin LsIA has also
shown reduced potency at 7 and 32 nAChRs when N-ter-
minally truncated (44), which corroborates the potential
importance of the N-terminal amino acid in -conotoxin
potency and selectivity.
The other two substitutions, P6A and F9A, caused an even
greater decrease in peptide activity on 34 nAChR than G1A.
Our NMR and CD data revealed that the [P6A]AuIB analog
structure is disrupted, but that of [F9A]AuIB is not. This is not
surprising considering the structural effect Pro has on protein
structures in general and -conotoxin structures in particular
(34). Therefore, we reasoned that the ability of Phe-9, but not
Pro-6, to reduce inhibition is due to Phe-9 specifically interact-
ing with the 34 nAChR.We found that the number of muta-
tions that reduce AuIB inhibition of the 34 nAChR is small
compared with other -conotoxins. For instance, alanine sub-
stitutions of almost all intercysteine residues in another
-conotoxin, Vc1.1, affected910 nAChR inhibition (35).We
also found no alanine mutants that inhibited the 34 nAChR
significantly more than native AuIB.
Aswell as substantially reducing34 inhibition, [F9A]AuIB
selectivity for nAChR subtypes also shifted. This indicates that
Phe-9 has a role in the peptide specific interaction with the
FIGURE8.Theeffectsof various substitutionsatposition9ofAuIBon its inhibitionof the34nAChRsubtype.A, CD spectra ofAuIB analogues inwhich
Phe-9 was substituted by various other residues. These spectra were similar to the spectrum of native globular AuIB, confirming that all of these analogues
retained their structure.B,bargraph showing inhibitionof34nAChRACh-evokedcurrent amplitudebynativeAuIBand its F9-substitutedanalogues (10M).
Note that inhibition is abolished if the position 9 residue is too small or too large. Still present, but reduced inhibition by the Tyr analog suggests that
hydrophobic interaction with the binding pocket at the 4 subunit is reduced because of steric hindrance. A random control mutation at position 12 of AuIB
([N12H]AuIB) does not attenuatemaximal inhibition byAuIB. Data represent themeans S.E., n 3–6. *** indicates p
 0.001 for relative reduction of current
inhibition versus native AuIB.
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34 nAChR and is needed to maintain selectivity for this par-
ticular subtype. Our docking simulation and MD calculations
showed that the () side of the 4 subunit is the site where
AuIB makes the most intermolecular contacts. Modeling also
suggested that Phe-9 is sandwiched by Trp-59 and Lys-61,
whichmay form a binding pocket on the4 subunit. Thismod-
el’s validity was corroborated by mutational analysis of the 4
subunit and position 9 of AuIB.
The Role of the 4 nAChR Loop D and Its Conserved Trypto-
phan in Binding to AuIB and the Pharmacology of Various
Ligands—Analysis of the 4 sequence (see also Fig. 9) indicates
that the AuIB binding pocket partially overlaps with the ACh
binding site. Residues 59–61 are situated on the 2 strand of
the 4 subunit and form the main functional part of loop D on
the complementary ACh-binding site component. The trypto-
phan of loop D (TrpD; Trp-59 in 4 numbering) is highly con-
served across different nAChR subunits and AChBPs and helps
form the aromatic box/cage of hydrophobic residues essential
for ACh binding and nAChR activation (45, 46). The residue in
position 2 relative to TrpD (Lys-61 in 4 numbering) is also
an important part of the ACh binding site (e.g. it corresponds
with Gln-57 in the 7 subunit).
Studies involving receptor mutations and co-crystallization
with AChBPs have shown that -conotoxins bind in the extra-
cellular part of nAChR subunit interface close to the ligand
binding site (47, 48). Usually -conotoxins do not rely on a
single critical residue/contact, and their binding determinants
can be found on both principal and complementary sides. For
instance, ImI has been proposed to bind to AChBP via a “net-
work of interactions” (49). Similar findings were obtained in an
earlier ImI-AChBP co-crystallization study (47) and using
docking simulations for ImI, GIC,MII, PnIA, andGID (50–52).
A study measuring ImI binding to mutated 7 nAChRs
reported a single dominant interaction between Arg-7 of ImI
and Tyr-195 of 7 as well as multiple weak interactions
between several other residues (53).
Many non-peptide ligands bind in the loopD region (54–57),
and in some cases, the residues homologous to 4-Lys-61 were
also suggested to be important. For example, differences in sen-
sitivity between 34 and 32 to receptor antagonists
dihydro--erythroidine and bungarotoxin and to agonists ACh
and nicotine were explained by the same difference in the
sequence (Lys-61 at 4; Thr-59 in 2 numbering) (55, 56). A
residue in this position underlies a difference between insect
and vertebrate nAChRs in sensitivity to neonicotinoid insecti-
cides (57). A difference in two residues preceding TrpD
accounts for a remarkable difference in human versus rat 34
nAChR sensitivity to the agonist 5-(trifluoromethyl)-6-(1-
methyl-azepan-4-yl)methyl-1H-quinolin-2-one (TMAQ) (54).
Using 32 receptor chimeras, determinants for MII cono-
toxin specificity were found on  and  subunits (58). Interest-
ingly, one of the determinants was mapped to loop D of the 2
subunit and identified as Thr-59 (homologous to 4-Lys-61).
Therefore, the Lys toThr substitution in the2 subunitwas one
factor that defined 2/4 selectivity for MII. BuIA conotoxin
has a different wash-off rate for 32 than 34 nAChRs. The
same difference in the sequence (Lys/Thr-59) in 4 and 2 was
also a determinant for the different wash-off rates for the vari-
ous nAChR subtypes (59).
Consistent with the studies mentioned above, our modeling
and experimental data show that the 4 single-point mutation
[K61A]4 only reduces AuIB inhibition, but [W59A]4 (TrpD)
completely abolishes it. Therefore, TrpD is essential forAuIB to
inhibit 34 nAChRs. TrpD involvement in nAChR pharma-
cology is well documented. Mutations of TrpD in AChBP have
been shown to affect its conformation as well as alter its
potency, desensitization, efficacy, and selectivity for various
ligands (60–64). However, its effects depend on the subunit
and ligand in question and aremore ambiguous thanmutations
of the principal subunit’s aromatic residues. For instance, the
effects of the TrpD mutation on ACh affinity for muscle
nAChRs differed between  and  subunits (20,000 versus
7,000-fold reduction) (61). TrpD mutation caused opposite
shifts in the potency of 4OH-GTS21 agonists in 7 and 42
nAChRs (62).
When expressed in Xenopus oocytes and tested by two-volt-
age clamp recordings, the [W59A]4 mutation dramatically
reduced the ACh-induced current without altering its kinetics.
To induce measurable currents, we had to use the saturating
ACh concentration of 2.5 mM instead of 50 M. In a previous
study we showed that high ACh concentration has practically
no effect on AuIB inhibition of 34, as this inhibition is non-
competitive (14).
There are examples where the binding/action of pharmaco-
logical agents is critically dependent on interaction with TrpD.
Apolipoprotein E inhibits 7 nAChRs via hydrophobic interac-
tions with 7 TrpD (Trp55 in 7 numbering) (64). Varenicline,
a smoking cessation drug, has been shown to interact with
2-TrpD in the 42 nAChR. TrpD substitution to Ala con-
verted varenicline from a partial to full agonist and abolished
varenicline-induced desensitization at high concentrations
(63).
Nature of AuIB-Phe-94-Trp-59 Interaction and Its Implica-
tions for AuIB Pharmacology—The sequence alignment of sev-
eral nAChR subunits (Fig. 9) centered at the AuIB binding
pocket shows that onlyTrpD (Trp-59 in4 numbering) is abso-
lutely conserved across the different subunits. However, substi-
tutions in theWLK pocket are often homologous. For example,
FIGURE 9. Protein sequence alignment of nAChR subunits. Sequence
alignments showing the ()(complementary) side of the main neuronal
nAChR subunits centered around loop D and its conserved tryptophan resi-
due TrpD, the main 4 subunit residue that interacts with Phe-9 of AuIB (4-
Trp-59). Absolutely conserved residues in the sequences are emphasized in
bold. Boxed residues are homologous to the WLK binding pocket on 4()
subunit. Residue numbering according to the4 subunit sequence is shown.
Note the ubiquitous conservation of tryptophan.
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instead of4-Lys at the TrpD2 position,9 and10 subunits
have a similar positively charged Arg. There is a single different
residue, Thr instead of Lys, between 2 and 4, and this can
cause differences in pharmacology. It is unlikely that Lys/Thr
substitution underlies AuIB selectivity for the 34 subtype, as
the [K61A]4 mutation only reduces inhibition, and AuIB is
not active at the 910 subtype when Lys is changed to an
essentially homologousArg. Interestingly, loopDof the3 sub-
unit has the sameWLK pocket as the 4 subunit.
AuIB could also bind at the non-canonical binding site ()/
(), as suggested for galanthamine and cocaine binding to
AChBP (65), anti-helminthic compound morantel binding to
32 nAChRs (66), and recently for-conotoxinVc1.1 binding
to 910 nAChRs (67). However, this is unlikely because the
dockingmodel does not support binding at a non-canonical site
and the [W59A]4 mutant loses inhibition despite identical
WLK pockets being available on the 3 subunit () side.
Another possibility could be that AuIB anchoring at the WLK
pocket is controlled by its interactions with the  subunit.
Our homology and MD-simulated model suggested that
Tyr-5 of AuIB interacts with the 3 subunit Gln-198. However,
[Q198A]3mutation did not affect AuIB inhibition, andmuta-
tion of its putative partner, Tyr-5-AuIB, did not reduce inhibi-
tion on the wild-type receptor. Mounting evidence suggests
that differences in three-dimensional structure across subunits
probably underlies distinct bond patterns for the same ligand
despite the presence of identical residues, as demonstrated for
nicotinic ligands (68, 69). This is certainly possible for larger
molecules, such as AuIB.
There is also the question of the mechanism behind AuIB
inhibition of nAChRs and how it can act non-competitively
despite overlapping with the ACh-binding site. At least two
larger peptides, apolipoprotein E and A1–42 amyloid, block
nAChRs non-competitively as well. In addition, apolipoprotein
E binds to loop D by interacting with TrpD (64, 70). AuIB may
be able to act non-competitively because it can bind to 34 in
the presence of ACh. Because TrpD may be involved in desen-
sitizing or transducing the gating signal (54, 63, 71), AuIB may
work by stabilizing the desensitized state or blocking the gating
signal. Another possibility is steric hindrance to the movement
of loop C, which is thought to be associated with agonist acti-
vation of nAChRs (47, 72).
What could be the nature of theAuIB-Phe-9 interactionwith
TrpD? It is well established that residues around ligand binding
sites and those that form the aromatic box in Cys-loop family
receptors oftenmake cation-	 bondswith their cognate ligands
(73). The reverse situation, when aromatic moieties of ligands
engage in a cation-	 bond formation with positively charged
residues of the receptor, is also possible (74). AuIB does not
have positively charged residues so cannot make a cation-	
bond with 4-Trp-59 (TrpD). A situation in which a positively
charged4-Lys-61 forms a cation-	 bondwith Phe-9 ofAuIB is
possible.However, our experimentwith single-pointmutations
of theWLKpocket showed that removing Lys-61 does not abol-
ish inhibition but that Trp-59mutation does. This suggests that
Trp-59 is indispensable for AuIB inhibitory effect and Lys-61
plays an auxiliary role in it.
Our experiments with second-generation AuIB mutants at
position 9 demonstrated that size and hydrophobicity/aroma-
ticity of the residue in this position are important for the pep-
tide to inhibit 34 nAChRs. Although simple hydrophobic
interaction of AuIB-Phe-9 and 4-Trp-59 is possible, it is more
likely that Phe-9 andTrp-59 interact via	-	 stacking due to the
deep insertion of Phe-9 in the WLK pocket. Because removing
positively charged Lys-61 reduces inhibition, it will likely inter-
act with Phe-9 of AuIB and/or stabilize AuIB-Phe-9 interaction
with 4-Trp-59. In conclusion, we identified determinants of
AuIB binding/action on the 34 nAChR.
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